BMO Capital analyst Kostas Biliouris has maintained their bullish stance on BEAM stock, giving a Buy rating yesterday.
Kostas Biliouris’s rating is based on the potential positive impact of Beam Therapeutics’ BEAM-302 program, which is expected to deliver a significant upside in the first half of 2025. The anticipation of a favorable readout for BEAM-302, particularly in achieving target AAT levels with acceptable safety, is seen as a key driver for the stock’s performance, potentially leading to a 30-50% increase in value.
Additionally, Beam Therapeutics’ progress in its SCD franchise, including updates on BEAM-101 and the initiation of BEAM-103 studies, further supports the Buy rating. The company’s strong cash position, which provides financial stability into 2027, and its ability to outperform its gene editing peers, also contribute to the positive outlook. The combination of these factors underpins Biliouris’s confidence in Beam Therapeutics’ growth potential.